From time to we may link to another location or social account from one of our accounts. Our linking to or following a non-Adamis website or social media account does not imply endorsement of those websites, social media accounts, properties or content thereon, or parent organizations, which are not sponsored by, affiliated with or controlled by Adamis. You access any such links at your own risk. Adamis makes no representations or warranties about the content of these links, or about the terms of use or privacy policies that may apply to such other sites.

Except as may be required by law, we undertake no duty to update any previous Company link or previous Company message on a social media platform.

Cautionary Statements Concerning Forward-Looking Information

The content referred to or linked to in the Company’s communication on the specified social media platform or outlet may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, expectations, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements may refer or relate to future events, results, possibilities or activities. Any such statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Actual future events and results may be materially different from the results anticipated by such forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the original date of such statements. Certain additional risks, uncertainties, and other factors relating to Adamis are described in greater detail in Adamis’ filings from time to time with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s website at http://www.sec.gov.

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit https://dmkpharma.com/

Check this page for the most recent updates regarding the merger process.